KalVista Pharmaceuticals (KALV) Leases (2019 - 2024)
KalVista Pharmaceuticals' Leases history spans 5 years, with the latest figure at $5.6 million for Q4 2024.
- For Q4 2024, Leases changed N/A year-over-year to $5.6 million; the TTM value through Dec 2024 reached $5.6 million, changed N/A, while the annual FY2024 figure was $6.9 million, N/A changed from the prior year.
- Leases for Q4 2024 was $5.6 million at KalVista Pharmaceuticals, down from $5.9 million in the prior quarter.
- Across five years, Leases topped out at $7.6 million in Q3 2023 and bottomed at $1.3 million in Q4 2020.
- The 4-year median for Leases is $5.7 million (2024), against an average of $4.5 million.
- The largest annual shift saw Leases surged 219.21% in 2020 before it fell 22.61% in 2024.
- A 4-year view of Leases shows it stood at $1.3 million in 2020, then grew by 26.67% to $1.7 million in 2021, then soared by 341.5% to $7.3 million in 2023, then fell by 23.62% to $5.6 million in 2024.
- Per Business Quant, the three most recent readings for KALV's Leases are $5.6 million (Q4 2024), $5.9 million (Q4 2024), and $5.9 million (Q3 2024).